|
Session 212: Frontiers in Pharmacology and Toxicology |
|
|
Day 2: Morning, July. 16, 2021 |
|
|
Chair |
Dr. Roberta Bursi, Vice President Model-Informed Drug Discovery Development, Vice President Acting Head Medical Devices, InsilicoTRIALS, Italy
|
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Title: InSilicoTrials.com: The Cloud Platform that Accelerates the Uptake of Computer Simulations for Testing Medicines and Medical Devices Dr. Roberta Bursi, Vice President Model-Informed Drug Discovery Development, Vice President Acting Head Medical Devices, InsilicoTRIALS, Italy |
|
09:00-09:25 |
Title: Opioid Therapy; When it is Caring and when it is Crippling? Dr. Olfat Zekry, Pharmacology Unit Coordinator, Pain Education Unit, Pain Management Research Institute, Sydney Medical School, The University of Sydney, Australia |
|
09:25-09:50 |
Speech Opportunity Available |
|
09:50-10:15 |
Title: Successful Outcome Following a Loading Dose of N-acetylcysteine to Treat Hepatotoxicity after Repeated Therapeutic Doses of Paracetamol Dr. Abdullah Altamimi, Children hospital –King Fahad Medical City, Saudi Arabia |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Title: Strategically Developing and Utilizing CDX and PDX Models for Supporting Anticancer Drug Development Dr. Jingqi Huang, Vice President of Pharmacology, Pharmaron, China |
|
11:20-11:45 |
Title: Pharmacochaperoning of Neurotransmitter Transporters in Health and Disease Dr. Sonja Sucic, Associate Professor, Medical University of Vienna, Australia |
|
11:45-12:10 |
Title: Ketamine/Propofol Admixture (“KETOFOL”) for Sedation: The Real Deal or Not? Dr. Nathan J Smischney, Assistant Professor, Department of Anesthesiology, Mayo Clinic, USA |
|
Session 222: Novel Analytical Technology in Drug Discovery |
|
|
Day 2: Morning, July. 16, 2021 |
|
|
Chair |
Dr. Anthony W. Coleman, Professor, University of Lyon, France |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Title: Electrophoretic Separation of Membrane Proteins in Supported n-bilayers: a Step toward a New Drug Discovery Platform Dr. Bernard Tinland, Research Director, CINaM - CNRS UMR 7325, France |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Title: The use of Multidisciplinary Research to Understand Bio-macromolecule Interactions with APIs Dr. Anthony W. Coleman, Professor, University of Lyon, France |
|
09:50-10:15 |
Title: TBD Dr. Jenny Lin, Chief Operating Officer, CMIC, USA |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Title: Characterization of Nanomaterials in Liquid Phase Using Particle Tracking Analysis Method Dr. Haruhisa Kato, Senior Researcher, National Metrology Institute of Japan (NMIJ),National Institute of Advanced Industrial Scienceand Technology (AIST), Japan |
|
11:20-11:45 |
Title: TBD Dr. Beom-Su Jang, Principal Investigator, Korea Atomic Energy Research Institute, South Korea |
|
11:45-12:10 |
Title: Determination of Dynamic Binding Capacity of Ion Channel Protein with Small Molecules by the Bio-layer Interferometry Assay Dr. Shangwei Hou, Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, China |
|
Session 312: CNS and Neurodegenerative Drug Targets |
|
|
Day 2: Morning, July. 16, 2021 |
|
|
Chair |
Call for Chair |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Title: Conventional and Advanced Imaging Biomarkers in Multiple Sclerosis Clinical Trials Dr. Daniel Bradley, Associate Director, Biogen, USA |
|
09:00-09:25 |
Title: TBD Dr. Miroslaw Latka, Assistant Professor, Wroclaw University of Science and Technology, Poland |
|
09:25-09:50 |
Title: TBD Dr. Hua Xu, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, China |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
Session 322: Drug Design and Synthesis |
|
|
Day 2: Morning, July. 16, 2021 |
|
|
Chair |
Dr. Sonali Rudra, Senior Principal Research Scientist, TCG Lifesciences Pvt. Ltd., India |
| Co-Chair | Dr. Didier Dubreuil, Professor, University of Nantes, France |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Title: iNKT Activation by Fluorinated Galactosylceramides Dr. Didier Dubreuil, Professor, University of Nantes, France |
|
09:25-09:50 |
Title: Novel Impiridones: Snthesis, Anticancer Activity and Structure-activity Relationships Dr. Antal Csampai, Professor, Institute of Chemistry, Eotvos Lorand University (ELTE), Hungary |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Title: EP4 Antagonists for Treatment against Cancer Dr. Sonali Rudra, Senior Principal Research Scientist, TCG Lifesciences Pvt. Ltd., India |
|
10:55-11:20 |
Title: Metabotropic Glutamate Receptor type 2 Positive Allosteric Modulators (mGlu2 receptor PAMs) as a Transformational Epilepsy Treatment Dr. Jose Maria Cid Nunez, Professor, Janssen Research and Development, Spain |
|
11:20-11:45 |
Title: TBD Dr. Salvatore Guccione, Professor, Central Drug Research Institute, Italy |
|
11:45-12:10 |
Title: TBD Dr. Nick Zhang, Chairman & CEO, MEDCDx (SuZhou) Translational Medicine Co. Ltd, China |
|
Session 412: CNS Diseases |
|
|
Day 2: Morning, July. 16, 2021 |
|
|
Chair |
Dr. Paolo Milia, Neurologist, University of Perugia, Italy |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Title: TBD Dr. Joan Fallon, CEO, Curemark, USA |
|
09:00-09:25 |
Speech Opportunity Available |
|
09:25-09:50 |
Title: TBD Dr. Paolo Milia, Neurologist, University of Perugia, Italy |
|
09:50-10:15 |
Title: A Child with Headache Attributed to Intracranial Neoplasm Dr. Fusun Ferda Erdogan, Professor, Erciyes University, Turkey |
|
10:15-10:30 |
Coffee Break |
| 10:30-10:55 |
Speech Opportunity Available |
| 10:55-11:20 |
Title: ‘Early Onset Alzheimer’s Disease from Clinical to Basic Science Dr. Popuri M. Krishna, Department of Psychiatry, Northern Ontario School of Medicine Psychiatry Department, Canada |
| 11:20-11:45 |
Title: Magnetic Navigation of Biodegradable Polymer-encapsulating Nanoparticles and Erythropoietin in Acute Central Nervous System Injury Dr. Chang Ho Hwang, Affiliated Professor, School of Electrical Engineering, University of Ulsan, South Korea |
| 11:45-12:10 |
Speech Opportunity Available |
|
Session 422: Therapeutic Antibodies and Vaccines |
|
|
Day 2: Morning, July. 16, 2021 |
|
|
Chair |
Dr. Mahmood Moshiri, President and CEO, Next Pharma Inc., Canada |
| Co-Chair | Dr. Thomas Boldicke, Professor, Helmholtz-Centre for Infection Research, Germany |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Title: Aspartyl (Asparaginyl) β-Hydroxylase (Aabh-Based Monitoring of Cancer Remission/Recurrence) Dr. Mahmood Moshiri, President and CEO, Next Pharma Inc., Canada |
|
09:00-09:25 |
Title: Comprehensive Host Cell Protein Analytical Solutions using Immunoassays and Mass Spectrometry Dr. Andrew Hanneman, Associate Director, Mass Spectrometry, Charles River Laboratories, USA |
|
09:25-09:50 |
Title: Antibodies directed against Complex Target Molecules Dr. Annika Schmid, Associate Director and Leader Discovery Programs, Morphosys AG, Germany |
|
09:50-10:15 |
Title: Development of Intracellular Antibodies Targeting Cancer Antigens Dr. Thomas Boldicke, Professor, Helmholtz-Centre for Infection Research, Germany |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Title: Recent Advances in ab initio Design of Antibodies Against Novel Targets Dr. Monica Berrondo, CEO, Macromoltek - Molecular simulations simplified, USA |
|
10:55-11:20 |
Title: Development of a Therapeutic Bispecific Antibody VEGF-PD-L1: Process Development and Non-clinical Studies Dr. Xiang Yang Zhu, CEO, Huabo Biopharm (Shanghai) Co., Ltd., China |
|
11:20-11:45 |
Title: Techniques for Selection and Verification of Highly Specific Antibodies Dr. Nileena Velappan, Researcher, Los Alamos National Laboratory, USA |
|
11:45-12:10 |
Speech Opportunity Available Abstract and Biography: Submit Here |
|
Session 441: New Challenges in Future Pharma Manufacturing |
|
|
Day 2: Morning, July. 16, 2021 |
|
|
Chair |
Call for Chair |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Title: Navigating through the Critical Path for Chemistry, Manufacturing and Controls (CMC) Dr. Elizabeth Kwong, President, Kwong Eureka Solutions, Canada |
|
09:25-09:50 |
Title: Selection and Development of Sterilization Processes Dr. Jeanne Moldenhauer, Vice President, Excellent Pharma Consulting, Excellent Pharma Consulting, USA |
|
09:50-10:15 |
Title: TBD Dr. Cornelia Thieme, Director, Global Manufacturing Sciences, Biogen, Switzerland |
|
10:15-10:30 |
Coffee Break |
Session 442: Novel Biosimilars Day 3: Morning, July. 17, 2021 Chair Dr. Andreas Seidl, Chief Operating Officer, LEUKOCARE AG, Germany Time 08:30-08:35 Chair's Introduction 08:35-09:00 Speech Opportunity Available 09:00-09:25 Title: Biosimilars in Europe, A Blueprint for Success Dr. Michael Reilly, Executive Director, Alliance For Safe Biologic Medicines, USA 09:25-09:50 Title: Innovative Formulation Strategies to Differentiate Biosimilars Dr. Andreas Seidl, Chief Operating Officer, LEUKOCARE AG, Germany 09:50-10:15 Title: TBD Mr. Andrew Spiegel, Executive Director, Global Colon Cancer Association, USA 10:15-10:30 Coffee Break Speech Opportunity Available Title: Biobetters: Using Innovation to Reap IP and Market Advantages over Competing Biosimilars in the U.S Dr. Robert V. Cerwinski, Partner, Goodwin Procter LLP, USA Title: TBD Dr. Leandro Gabriel Mieravilla, Global Manager, Cassara Biotech, Canada
Abstract and Biography: Submit Here
10:30-10:55
Abstract and Biography: Submit Here
10:55-11:20
11:20-11:45
|
Session 213: Drug Metabolism and Interactions |
|
|
Day 2: Afternoon, July. 16, 2021 |
|
|
Chair |
Dr. Gianluca Catucci, University of Torino, Italy |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: In-silico Methodology that Outperforms Lab Methods in Predicting Human Clinical ADME/PK Dr. Urban Fagerholm, CEO, PROSILICO, Sweden |
|
14:00-14:25 |
Title: The Biochemistry of Human Flavin-containing Monooxygenases: Implications for Drug Metabolism Dr. Gianluca Catucci, University of Torino, Italy |
|
14:25-14:50 |
Speech Opportunity Available |
|
14:50-15:15 |
Title: Impact of Conjugated Flavonoid Metabolites on Drug Transporters and Biotransformation Enzymes Dr. Agnes Telbisz, Senior Research Fellow, Institute of Enzymology, RCNS-HAS, Hungary |
|
15:15-15:30 |
Coffee Break |
| 15:30-15:55 |
Title: In Vivo/ex Vivo Monitoring of Drug-Drug Interactions in the Physiological Barriers Dr. Franciska Erd, Senior Scientist, Faculty of Information Technology and Bionics, Pázmány Péter Catholic University, Hungary |
| 15:55-16:20 |
Title: Modelling Inactivation Parameters From Time-Dependent Inhibition Improves Clinical DDI Prediction Compared to Standard Practice Dr. Jaydeep Yadav, Scientist, Pharmacokinetics and Drug Metabolism, Amgen, Inc., USA |
| 16:20-16:45 |
Title: Radiation Drug Interactions with an Emphasis on the Interactive Toxic and Therapeutic Effects of Radiation Therapy and Tyrosine Kinase Inhibitors Dr. Gerald Sokol, Associate Professor of Medicine and Clinical Pharmacology, USUHS, USA |
| 16:45-17:10 | Speech Opportunity Available Abstract and Biography: Submit Here |
|
Session 223: Nanotechnology in Drug Discovery |
|
|
Day 2: Afternoon, July. 16, 2021 |
|
|
Chair |
Call for Chair |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: TBD Dr. Philippe Tschopp, Head of Business Development, Glatt Pharmaceutical Services GmbH & Co. KG, Germany |
|
14:00-14:25 |
Title: TBD Dr. Imran Y. Saleem, Professor, Liverpool John Moores University, Programme Leader in MSc Cosmetic, UK |
|
14:25-14:50 |
Title: Folate and Antifolate SERS-active Nanovectors: Quantitative Drug Nanostructuring and Selective Cell Targeting for Effective Theranostics Dr. Fabio Domenici, Assistant Professor, Department of Chemical Sciences and Technology, University of Rome, Italy |
|
14:50-15:15 |
Speech Opportunity Available |
|
15:15-15:30 |
Coffee Break |
|
Session 313: Autoimmune and Inflammation Drug Targets |
|
|
Day 2: Afternoon, July. 16, 2021 |
|
|
Chair |
Dr. Joseph Holoshitz, Professor of Internal Medicine, Division of Rheumatology, University of Michigan School of Medicine, USA |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Keynote Speech Title: New Technologies using Immune Cells to Inform on Human Disease Status Dr. John J. Miles, Professor, James Cook University, Australia |
|
14:00-14:25 |
Title: A New Therapeutically-Targetable Pathway in Rheumatoid Arthritis Dr. Joseph Holoshitz, Professor of Internal Medicine, Division of Rheumatology, University of Michigan School of Medicine, USA |
|
14:25-14:50 |
Title: Microglia and Mast Cells Generate Proinflammatory Cytokines in the Brain and Worsen Inflammatory Status Dr. Stefano Martinotti, Professor, Department of Medical, Oral and Biotechnologic Sciences, Università degli Studi G. d'Annunzio Chieti e Pescara, Italy |
|
14:50-15:15 |
Title: Influence of Heat Shock Proteins in Individual Sensitivity of Human Neutrophils to Heat Stress Dr. Victor F. Semenkov, Associate Professor, Department of Immunology, Pirogov Russian National Research Medical University, Russia |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: Role of Heat Shock Protein 90 in Autoimmune Inflammatory Rheumatic Diseases Dr. Michal Tomcik, Associate Professor, Institute of Rheumatology, Czech Republic |
|
15:55-16:20 |
Title: TBD Dr. Petr Maly, Group Leader, Institute of Biotechnology of the Czech Academy of Sciences v.v.i., Czech Republic |
|
16:20-16:45 |
Title: Immunoproteasome Inhibitors Affect Human Immune Cell Viability Dr. Katrien Pletinckx, Head of Laboratory, Grünenthal GmbH, Germany |
|
16:45-17:10 |
Speech Opportunity Available |
|
Session 323: Screening and Lead Optimization |
|
|
Day 2: Afternoon, July. 16, 2021 |
|
|
Chair |
Call for Chair |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Speech Opportunity Available |
|
14:25-14:50 |
Title: The Discovery and Characterisation of Highly Selective and in Vivo Capable Inhibitors of the Second Bromodomains of the BET Family of Proteins Mr. Alex Preston, Scientific Leader, GSK, UK |
|
14:50-15:15 |
Title: TBD Dr. Zhenwei Su, Senior Scientist, Biomedicine Design, Pfizer, Inc., USA |
|
15:15-15:30 |
Coffee Break |
|
Session 413: Infectious Diseases |
|
|
Day 2: Afternoon, July. 16, 2021 |
|
|
Chair |
Dr. Michael Ovadia, Professor, Tel Aviv University, Israel
|
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-13:55 |
Title: Chagas Disease Drug Discovery: Multiparametric Lead Optimization Through Collaborative Project Dr. Gilles Courtemanche, Associate Director, Antimicrobials Unit, BIOASTER, France |
|
13:55-14:15 |
Title: Cinnamon Fraction CEppt Iinhibits Human Influenza H1N1 and Bird Flu H5N1 Leading to Vaccination of the Animals Dr. Michael Ovadia, Professor, Tel Aviv University, Israel |
|
14:15-14:35 |
Title: Antibacterial Drug Discovery and Development Programs, Preclinical and Clinical Services at NIAID Dr. Zuoyu Xu, Program Officer, Bacteriology and Mycology, National Institute of Allergy and Infectious Diseases (NIAID), NIH/DHHS, USA |
|
14:35-14:55 |
Speech Opportunity Available |
| 14:55-15:15 |
Title: Nanoformulated PI3-Kinase Inhibitors to Prevent Infection – driven Liver Failure Dr. Michael Bauer, Professor, Center for Sepsis Control and Care, University Hospital Jena, Germany |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:50 |
Title: The Role of Wildlife in the Transmission of Parasitic Zoonoses in Peri-urban Areas Dr. Ute Mackenstedt, Professor, Parasitology Unit, University of Hohenheim, Germany |
|
15:50-16:10 |
Title: AMR: The Links Between Antibiotic Resistance and Disinfectant Resistance Dr. Andrew Kemp, AK Medical Ltd, UK |
|
16:10-16:30 |
Title: MazF toxin: A Magic potion for Bacterial Sleeping Pan-coronavirus Fusion Inhibitors for Prevention and Treatment of COVID-19 Dr. Adriana Renzoni, Service of Infectious Diseases, University Hospital and Medical School of Geneva, Switzerland |
|
16:30-16:50 |
Title: Pan-coronavirus Fusion Inhibitors for Prevention and Treatment of COVID-19 Dr. Shibo Jiang, Professor and Director, Institute of Medical Microbiology, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Fudan University, China |
| 16:50-17:10 | Title: mcr-1, mcr-3 , Carbapenemase and CTX-M Genes in Carbapenemase Producing Klebsiella Pneumoniae Isolated from Humans in Thailand Dr. Worada Samosornsuk, Associate Professor, Department of Medical Technology, Thammasat University, Thailand |
| 17:10-17:30 |
Speech Opportunity Available |
|
Session 414: Cardiovascular Diseases |
|
|
Day 2: Afternoon, July. 16, 2021 |
|
|
Chair |
Dr. Karin Schutze, CSO, CellTool GmbH, Germany |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: Quality Assurance for Cell based Therapeutics such as T-cells, Blood Products and 3D Tissues Dr. Karin Schutze, CSO, CellTool GmbH, Germany |
|
14:00-14:25 |
Speech Opportunity Available |
|
14:25-14:50 |
Speech Opportunity Available Abstract and Biography: Submit Here |
|
14:50-15:15 |
Title: TBD Dr. Tamas Alexy, Department of Medicine, Division of Cardiology, University of Minnesota, USA |
|
15:15-15:30 |
Coffee Break |
| 15:30-15:55 |
Title: Evidence of NLRP7 Direct Involvement in Gestational Choriocarcinoma Development: Clinical, in vitro and in vivo Investigations Dr. Nadia Alfaidy, Senior Researcher, Director of research at INSERM, France |
| 15:55-16:20 |
Title: Anticoagulant and Antiplatelet Therapies for Children in the 21st Century ---- Their Challenges and Rewards Dr. Masato Takahashi, Clinical Professor, U. Washington School of Medicine, USA |
| 16:20-16:45 | Title: Trumanshow- A Screening Tool for Early Detection of Aortic Dissections in the Emergency Department Dr. Rama Subrahmanyam, Emergency Physician, University Hospitals of Leicester, UK |
| 16:45-17:10 |
Speech Opportunity Available |
|
Session 415: Diabetes and Other Metabolic Disorders |
|
|
Day 2: Afternoon, July. 16, 2021 |
|
|
Chair |
Dr. Miriam Kidron, CSO, Oramed Pharmaceuticals, Israel |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: Therapeutic Approaches for Non-Alcoholic Steatohepatitis (NASH) Dr. Ralf Glatthar, Director, Novartis Pharma AG, Switzerland |
|
14:00-14:25 |
Title: Overcoming the Barriers to Oral Insulin Development: A Point in Time Assessment Dr. Miriam Kidron, CSO, Oramed Pharmaceuticals, Israel |
|
14:25-14:50 |
Title: Is magnesium an Effective Prophylaxis against Recurrent Calcium Oxalate Nephrolithiasis? Dr. Michel Normand, Nephrologist, Private Hospital, France |
|
14:50-15:15 |
Title: Novel Screening Methods for Prediabetes and Type 2 Diabetes Dr. Serge Bottari, Grenoble-Alps University, France |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: Primary Hyperoxaluria – A New Promising Treatment for a Fatal Disease Dr. Elisabeth Lindner, President, OxThera, USA |
|
15:55-16:20 |
Title: Changes in Trends of Epidemiological Data (Incidence, Prevalence, Mortality) among Pharmacologically Treated T2DM-patients in Hungary between 2001-2016 Dr. Peter Kempler, Professor, Department of Medicine, Semmelweis University, Hungary |
|
16:20-16:45 |
Speech Opportunity Available |
|
16:45-17:10 |
Title: New Era in Management of Type 2 Diabetes Dr. Mohsen Khalid, National Institute of Diabetes and Endocrinology, Egypt |
|
Session 443: CMO/CRO and Outsourcing Services |
|
|
Day 3: Afternoon, July. 16, 2021 |
|
|
Chair |
Dr. Albin (Jim) Nelson, Senior Principal/Owner, Schwegman Lundberg Woessner P.A., USA |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: Occupational Medicine and Addiction in Severe Apnea Syndrom Patients: How to Prevent the Vicious Circle? Dr. Raphael Serreau, Professor, SMP PARADICT-O Orléans Métropole INSERM EA Psycomadd Paris Sud Saclay, France |
|
14:00-14:25 |
Speech Opportunity Available |
|
14:25-14:50 |
Title: Top Ten Points for a Researcher to Win a Patent Grant or Why Do I Need a Patent Anyway? Dr. Albin (Jim) Nelson, Senior Principal/Owner, Schwegman Lundberg Woessner P.A., USA |
|
14:50-15:15 |
Speech Opportunity Available |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: TBD Dr. Abhay Deshpande, Director, Global Innovation & Strategy, JRF Global, India |
|
15:55-16:20 |
Speech Opportunity Available |
|
16:20-16:45 |
Title: TBD Ms. Marie Walsh, European Patent Attorney, Hanna Moore + Curley, Ireland |
|
16:45-17:10 |
Speech Opportunity Available |
© 2003-2021 All rights reserved by BITeomics |